Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia

Achalia, Rashmin; Chaturvedi, Santosh K.; Desai, Geetha; Rao, Girish N; Prakash, Om

doi:10.1016/j.ajp.2013.12.010

Cited by 19 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the prevalence is greater than that found in Arab among psychotic patients treated with first-generation antipsychotic which shows the prevalence was 5.9% [9]. The present study result is also lower than the findings of studies done in Turkey and Indian [13,14] in which the prevalence of first-generation antipsychotics induced TD was 22.5% and 26.4% respectively. This variation could be due to different possible reasons like characteristics of the participants.…”

Section: Discussioncontrasting

confidence: 87%

Prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital, psychiatric clinic, Ethiopia: Institution based a cross-sectional study

Abdeta

Tolessa

Tsega

2019

Preprint

View full text Add to dashboard Cite

Background Tardive Dyskinesia is described as a movement disorder that can be caused by the prolonged use of antipsychotics. It is a permanent condition that affects quality of life. However, studies on TD among psychiatric patients in Ethiopia are limited. The objective of this study was to determine the prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital (JUSH) psychiatric clinic, Jimma, South west Ethiopia.Method Hospital based cross-sectional study was conducted using Abnormal Involuntary Movement Scale (AIMS) and Schooler and Kane research criteria to identify cases of first-generation antipsychotic-induced TD among 151 psychiatric outpatients on first-generation antipsychotics at Jimma University Specialized Hospital psychiatric clinic. Simple random sampling method was employed to select subjects from a total of 912 patients on follow-up and logistic regression analysis was employed to identify associated factorsResult In our study the prevalence of first-generation antipsychotic induced TD was 14.6% (95%CI: 10.76%, 18.4%). In the final model multivariate logistic regression analysis revealed that age (AOR 4.5, 95%CI: 9.7, 20.4), current smoking cigarettes (AOR 1.4, 95%CI: 2.6, 7.8) and chlorpromazine equivalent dose (AOR 6.5, 95%CI: 2.6, 26.8) had statistically significant association with first-generation antipsychotic induced TD.Conclusions Considerable number of psychiatric patients were suffered from first-generation antipsychotic induced TD. Age and current smoking cigarettes and chlorpromazine equivalent dose had significant association with first-generation antipsychotic induced TD. Therefore, stakeholders should consider and appropriately address these statistically identified associated factors in order to reduce antipsychotic induced TD.

show abstract

Section: Discussioncontrasting

confidence: 87%

Prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital, psychiatric clinic, Ethiopia: Institution based a cross-sectional study

Abdeta

Tolessa

Tsega

2019

Preprint

View full text Add to dashboard Cite

show abstract

“…On the other hand, several clinical variables have consistently predicted TD occurrence in schizophrenia in observational studies, RCTs, and reviews; these include anticholinergic medication; older age; intermittent antipsychotic treatment; high cumulative dose; higher negative, cognitive, and affective symptoms; and early movement side effects 88–91. At present, no specific SGA can be considered as conferring a higher TD risk than others in schizophrenia 92…”

Section: Methodsmentioning

confidence: 99%

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Solmi

Murru

Pacchiarotti

et al. 2017

TCRM

337

244

View full text Add to dashboard Cite

Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients – psychosocial functioning, quality of life, and recovery. These drugs are no longer limited to specific Diagnostic and Statistical Manual of Mental Disorders (DSM) categories. Evidence indicates that SGAs show an improved safety and tolerability profile compared with FGAs. The incidence of treatment-emergent extrapyramidal side effects is lower, and there is less impairment of cognitive function and treatment-related negative symptoms. However, treatment with SGAs has been associated with a wide range of untoward effects, among which treatment-emergent weight gain and metabolic abnormalities are of notable concern. The present clinical review aims to summarize the safety and tolerability profile of selected FGAs and SGAs and to link treatment-related adverse effects to the pharmacodynamic profile of each drug. Evidence, predominantly derived from systematic reviews, meta-analyses, and clinical trials of the drugs amisulpride, aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, CPZ, haloperidol, loxapine, and perphenazine, is summarized. In addition, the safety and tolerability profiles of antipsychotics are discussed in the context of the “behavioral toxicity” conceptual framework, which considers the longitudinal course and the clinical and therapeutic consequences of treatment-emergent side effects. In SMI, SGAs with safer metabolic profiles should ideally be prescribed first. However, alongside with safety, efficacy should also be considered on a patient-tailored basis.

show abstract

“…9 Studies also indicate that up to 50% of all patients treated with some antipsychotic medications for mental illness will develop drug-induced Tardive Dyskinesia. 10 The prevalence of drug-induced TD accounts for 25% in the study from Canada, 11 28.4% from Netherland, 6 from California 63%, 12 from Poland (11.9%), 13 in France (1.4%), 14 26.4% finding from India, 15 in Serbia 24% to 30% 16 and 5.9% as the finding from Saudi Arabia. 17 A study done in Kenya among 164 psychiatric outpatients at Mathari Hospital indicates that the prevalence of drug-induced TD was 11.9% 18 whereas the prevalence of drug-induced TD in University of Port Harcourt Teaching Hospital, Nigeria was (5.8%) 19 and from a crosssectional study done on 377 psychotic patients in Ethiopia, 2014, using AIMS reveals that the prevalence of psychotropic medications-induced TD was 45 (11.9%).…”

Section: Tardive Dyskinesiamentioning

confidence: 87%

<p>Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia</p>

Kumsa¹,

Girma²,

Alemu³

et al. 2020

CPAA

View full text Add to dashboard Cite

Background: Tardive dyskinesia (TD) remains a significant burden especially among patients taking psychotropic medications, and it is associated with adverse effects that can lead to subjective suffering, stigma, poor compliance to medication, and poor quality of life. However, it is unrecognized and overlooked in clinical settings. So, this study aimed to assess the magnitude of tardive dyskinesia and associated factors among mentally ill patients attending follow-up treatment at

show abstract

Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia

Cited by 19 publications

References 40 publications

Prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital, psychiatric clinic, Ethiopia: Institution based a cross-sectional study

Prevalence and associated factors of Tardive dyskinesia among psychiatric patients on first-generation antipsychotics at Jimma University specialized hospital, psychiatric clinic, Ethiopia: Institution based a cross-sectional study

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

<p>Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia</p>

Contact Info

Product

Resources

About